Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of ifinatamab deruxtecan I-DXd in adults with unresectable advanced or metastatic esophageal squamous cell carcinoma ESCC who have experienced disease progression after treatment with platinum-based chemotherapy and immune checkpoint inhibitors. This phase 3 clinical trial compares I-DXd to the investigators choice of chemotherapy in this patient group to assess overall survival benefits. Participants are randomly assigned to receive either intravenous infusions of I-DXd at 12 mgkg every 21 days or investigator-selected chemotherapy drugs such as docetaxel, paclitaxel, or irinotecan hydrochloride. Treatment cycles repeat every three weeks, continuing until disease progression or other study endpoints. The study will measure overall survival, progression-free survival, objective response rate, duration of response, disease control rate, quality of life changes, safety events, and pharmacokinetic parameters for up to approximately 54 months. Throughout the study, participants will undergo regular assessments including imaging scans to measure tumor lesions, quality of life questionnaires, and safety monitoring for adverse events. Blood samples will be collected to analyze drug levels and immune responses. The studys main outcome is overall survival from randomization to death from any cause. Participants health and response to treatment will be followed closely during and after treatment for up to 54 months, with continued monitoring of safety and effectiveness measures.
Actively Recruiting
This research aims to better understand patients diagnosed with aortic valve disease, including aortic insufficiency and aortic valve stenosis, during hospitalization. The study is a multicenter cohort study focused on evaluating risk factors that affect patient outcomes. Researchers will use this information to develop a model that can help guide clinical decisions for people with these heart valve conditions. Participants diagnosed with aortic valve disease will be followed over time to observe their health outcomes. The study will monitor events such as all-cause death and cardiovascular complications, including whether patients undergo aortic valve replacement. No specific treatments or interventions are assigned, as this is an observational study. During the study, participants will be observed from baseline until death or the end of the follow-up period. Researchers will collect data on mortality and cardiovascular events to analyze prognostic risk factors. The primary outcome is all-cause mortality, while secondary outcomes include cardiovascular death and valve replacement. This ongoing observation will help improve understanding of the disease progression and patient prognosis.
Actively Recruiting
This research aims to improve the evaluation of radiation oropharyngeal mucositis, a painful side effect experienced by patients undergoing radiotherapy for head and neck tumors. The study compares a new four-type classification system based on histopathological changes with traditional grading methods. It also explores changes in blood markers related to different types of mucositis by using residual blood samples from patients. The study is observational and does not require any extra visits or tests beyond routine clinical care. It is divided into three parts first, comparing the consistency of different mucositis assessment methods among doctors second, evaluating the stability of these assessments across multiple doctors and third, comparing doctor assessments using the new classification with patients self-assessments. Patients are assessed every 1 to 2 weeks during radiotherapy. Participants will provide consent for data collection, including routine diagnosis and treatment information. Researchers will measure the consistency between doctors evaluations and between doctors and patients over up to three years. Patient and doctor satisfaction with the assessment methods will also be recorded. The main outcome is inter-rater consistency among doctors, with monitoring continuing throughout the study period.
Actively Recruiting
Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.
Actively Recruiting
Rheumatoid arthritis RA is a leading cause of disability, especially among Chinese women, and early treatment is crucial to improving outcomes. This research focuses on patients with a specific type of RA called synovial myeloid stromal type, which is linked to more severe disease and poorer response to standard treatment. The study aims to evaluate whether early intensified treatment can improve disease control in these patients by using a new synovial pathology classification to guide therapy. The study compares two treatment approaches for adults with moderate to severe active RA of the synovial myeloid stromal type. One group receives methotrexate combined with tofacitinib, while the other group receives methotrexate alone. Methotrexate is taken orally once a week at doses of 10-15 mg, and tofacitinib is taken orally twice a day at 5 mg. The treatment period lasts 12 weeks, followed by a 48-week follow-up phase. This randomized, open-label study is conducted across multiple centers. Participants will undergo assessments of disease activity, joint function, and safety at various points throughout the study, including weeks 4, 8, 12, 24, 36, and 48. Researchers will measure the proportion of patients achieving at least 20% improvement in RA symptoms at 12 weeks, along with changes in disease activity scores and joint damage progression at 48 weeks. The study also explores serum biomarkers to develop a precise diagnostic system. Overall participation lasts about 60 weeks from treatment start through follow-up.
Actively Recruiting
Head and neck squamous cell carcinoma SCC is a common cancer worldwide, causing many new cases and deaths each year. Radiotherapy is important to control the recurrence of these tumors, but it often causes acute inflammation such as radiotherapy-induced oral mucositis RIOM, which can affect patients quality of life and treatment effectiveness. Researchers are studying plasma levels of Serum amyloid A1 SAA1, a protein linked to inflammation, to see if it can help predict the onset and severity of RIOM early in patients receiving radiotherapy for nasopharyngeal carcinoma or other head and neck tumors. This is a prospective, multicenter, observational study where participants with nasopharyngeal carcinoma or head and neck tumors who need radiotherapy will be followed. Plasma SAA1 levels will be measured to explore their ability to predict radiotherapy-induced oral mucositis. The study will track the development, start time, duration, and severity of oral mucositis along with other side effects of radiotherapy and tumor response over a period of up to three years. Participants will be monitored throughout radiotherapy and afterward for up to three years to assess different grades of oral mucositis and other side effects. The study will collect clinical data, observe tumor response, and evaluate plasma SAA1 levels as a biomarker. This long-term observation aims to improve early screening and prevention strategies for radiotherapy-induced oral mucositis, enhancing patient care during and after radiotherapy.
Actively Recruiting
Researchers are conducting a multicenter study involving patients diagnosed with tricuspid regurgitation during hospitalization. The study aims to evaluate the risk factors that affect the prognosis of these patients and to develop models that predict outcomes. The main focus is to understand all-cause death as the primary outcome, alongside cardiovascular events as secondary outcomes. This observational study follows patients over an average of five years to monitor their health outcomes. There are no specific treatment interventions, as the study observes patients health status and events as they occur naturally without assigning any experimental therapies or procedures. Participants will be followed through regular observation during the study period, during which researchers will collect data on mortality, cardiovascular deaths, and hospitalizations for heart failure. The study involves continuous follow-up to track these events and analyze their relationships with risk factors. Total participation may last about five years, allowing detailed long-term monitoring of patient outcomes.